Gain Therapeutics, Inc. (GANX)
NASDAQ: GANX · Real-Time Price · USD
2.025
+0.075 (3.85%)
May 8, 2025, 4:00 PM EDT - Market closed
Gain Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Gain Therapeutics stock have an average target of 8.20, with a low estimate of 6.00 and a high estimate of 12. The average target predicts an increase of 304.94% from the current stock price of 2.03.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 28, 2025.
Analyst Ratings
The average analyst rating for Gain Therapeutics stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 3 | 3 | 3 | 3 | 3 |
| Buy | 2 | 2 | 2 | 2 | 3 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 5 | 5 | 5 | 6 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $6 | Strong Buy | Maintains | $6 | +196.30% | Mar 28, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +295.06% | Mar 17, 2025 |
| Scotiabank | Scotiabank | Buy Initiates $12 | Buy | Initiates | $12 | +492.59% | Mar 7, 2025 |
| Roth MKM | Roth MKM | Strong Buy Maintains $7 | Strong Buy | Maintains | $7 | +245.68% | Dec 24, 2024 |
| Roth MKM | Roth MKM | Strong Buy Initiates $7 | Strong Buy | Initiates | $7 | +245.68% | Dec 5, 2024 |
Financial Forecast
Revenue This Year
40.80K
Revenue Next Year
n/a
from 40.80K
EPS This Year
-0.81
from -0.89
EPS Next Year
-1.00
from -0.81
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 210,000 | n/a | n/a | ||
| Avg | 40,800 | n/a | n/a | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.58 | -0.41 | -0.42 | ||
| Avg | -0.81 | -1.00 | -1.09 | ||
| Low | -1.13 | -1.38 | -1.70 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.